{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Adenocarcinoma colorrectal metastásico.","Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Adenocarcinoma Colorrectal Metastásico."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2030383"],"location":["Spain"],"study_start_month":["6"],"keyword":["Oxaliplatino","Capecitabina","Oxaliplatin","First line","Capecitabine","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.","description":"The purpose of this study is to determinate progression free survival after 9 months of treatment.","dates":{"creation":"2006-06-15"},"accession":"2030383","cross_references":{"ClinicalTrials___gov":["NCT00345696"],"EU Clinical Trials Register":["2005-006171-12"]}}